Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry
Background: Tolvaptan is the only approved treatment in Canada for slowing the progression of kidney enlargement and kidney function decline in people with autosomal dominant polycystic kidney disease (ADPKD). The Canadian Medical Assessment of Jinarc® Outcome Registry (C-MAJOR) registry evaluating...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2026-01-01
|
| Seri Bilgileri: | Canadian Journal of Kidney Health and Disease |
| Online Erişim: | https://doi.org/10.1177/20543581251404128 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|